Truist raised the firm’s price target on Kymera Therapeutics (KYMR) to $68 from $53 and keeps a Buy rating on the shares. The firm has updated its model to reflect $1.9B in peak adjusted sales estimated for KT-621s, reflecting increased conviction for KT-621 program over longer term and Phase 1b data readout expected over the near-term, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $70 from $60 at H.C. Wainwright
- Kymera Therapeutics: Promising Developments and Buy Rating Amidst Significant Clinical Advancements
- Kymera Therapeutics to present on KT-621 at EADV Congress
- Kymera Therapeutics initiated with an Overweight at Barclays
- Kymera Therapeutics initiated with an Outperform at RBC Capital